York Pharma Share Discussion Threads

[topinfo] 21/4/2009 21:23

Come on YRK give us a clue.??????????????

[topinfo] 19/4/2009 23:23

I think we will get either an update this week or a relisting and update after accounts posted and offer confirmed or details on progress of offer and short term funding.

[topinfo] 17/4/2009 00:34

Product Pipeline is great, this will not be allowed to go under.

[topvest] 15/4/2009 20:38

I would guess at close to zero, I'm afraid. Be interesting to see what happens.

[topinfo] 15/4/2009 19:48

A new update would be nice.

[topinfo] 07/4/2009 22:08

So what we going to get then in plain hard cash???

[handycam] 07/4/2009 09:08

I shall run with the tenuous chance of Sir Chris wanting to get his Derms back.

Did not know about the $6m outstanding.

[topinfo] 07/4/2009 08:51

Only paid 2.25p so Im happy with that but loads of others wont be. I wonder when it will relist after suspension.?

[handycam] 07/4/2009 08:42

Last year ulu were a dollar fifty-five...

[topinfo] 07/4/2009 08:36

So how much will we get per share?

[handycam] 07/4/2009 08:34

The reason a tiddler from texas knows of YRK is because they licence Zindaclin to Derms.

[handycam] 07/4/2009 08:32

19.9m AMEX:ULU shares values YRK at $4.14m or £2.8m / 61m shares (before conv.) = 4.59pps max.

They too lose money, aLTRAZEAL.COM being their abasol.

[smelleroo] 07/4/2009 06:53

ULURU Inc. (NYSE Amex: ULU) today announced that it has signed a non-binding offer letter to acquire York Pharma plc ("York"). York is a United Kingdom based skin care company with operations or distribution networks throughout Europe with an established revenue base.


One of the conditions to ULURU making any offer is that the outstanding debt of York (currently being U.S. $6 million of unsecured Convertible Loan Notes 2014, together with accrued interest thereon) shall be converted into ordinary shares of York prior to the closing of any offer. Under the indicative terms set out in the non-binding offer letter, ULURU shareholders would own approximately 77% of the combined company. York shareholders (as enlarged by the conversion of the outstanding debt) would own approximately 23% of the combined company, which would result in ULURU issuing approximately 19.9 million shares.


In conjunction with the signing of the non-binding offer letter, ULURU entered into a series of agreements involving the granting of a revolving line of credit to York. As security for advances made against this line of credit ULURU received a security interest in substantially all of the assets of York.


ULURU and York have not executed definitive documentation relating to any acquisition transaction. There can be no assurance that the parties will enter into definitive documentation for such an acquisition transaction.


ULURU is pursuing a potential acquisition as strategically this is important and would be expected to provide the following benefits to ULURU:


-- Significantly enhance the commercial capability of the Company by
creating an integrated U.S. and European marketing and sales
infrastructure
-- Afford the ability to leverage the existing sales and marketing
organizations
-- Create a larger company with an established revenue base providing an
effective vehicle to more rapidly grow both internally and from selected
product acquisitions
-- Enhance the profile of the Company better positioning us to be a partner
of choice for skin care licensing and product acquisition opportunities
-- Better positions the Company to attract capital market support from both
U.S. and European institutions
-- Offers the potential to more rapidly drive growth in shareholder value
-- Offers the potential for significant administrative synergy savings




Commenting on the potential acquisition, Renaat Van den Hooff, President and CEO of ULURU stated, "The potential benefits to be derived from this proposed acquisition will significantly accelerate the maturation of ULURU into a commercially based company with a strong revenue base. This revenue base will positively position the company for more rapid growth both in the United States and Europe."

smell

[topinfo] 03/4/2009 13:50

I know 100% that this will be back trading very soon, maybe with the news we have been waiting for about confirmed takeover or secured funding. 3.5p will be a distant memory soon.

[roorontev] 03/4/2009 08:20

LOL....Gone to collect his bonus?......

[ursamajorra] 03/4/2009 08:06

And where is nobby?

company stooge

[topinfo] 01/4/2009 15:22

Just seen this update...sounds promising. Could relist within days.

"Market update (York Pharma)



TIDMYRK

RNS Number : 8239P
York Pharma plc
31 March 2009

?


York Pharma Plc (the "Company")


Market update


On 20 March 2009, the Board of the Company announced that it was in discussions
with two potential offerors and that these discussions included the provision of
the necessary short term funding facilities to allow the Company to continue
trading through the period needed to complete any formal offer for the Company
under the Takeover Code. Discussions with both parties have continued.


The Board announces that one of the potential offerors (the "Lender") has today
entered into an agreement with the Company to provide the Company with a secured
revolving credit facility of up to US$1,000,000 (the "Facility"). The Facility
is repayable, along with accrued interest, upon the earlier of (i) 6 months from
the date of the first draw down under the facility agreement; and (ii) 30 days
after the termination of any potential offer discussions. After the initial
drawdown, any subsequent drawdowns under the Facility will be at the sole and
absolute discretion of the Lender.


The Board believes that the drawdown of the full Facility should allow the
Company to continue trading through the period needed to complete any formal
offer for the Company by the Lender under the Takeover Code. The Board of the
Company wishes to stress that there can be no certainty that the discussions
will lead to an offer being made for the Company.


The Board will provide a further update as and when appropriate.


For more information please contact:


+--------------------------------------+--------------------------------------+
| York Pharma Plc | Tel: [phone] |
| Richard Anderson, Chief Executive | |
| Officer | |
| Ian Miscampbell, Chief Financial | |
| Officer | |
| | |
+--------------------------------------+--------------------------------------+
| Collins Stewart Europe Limited | Tel: [phone] |
| Hugh Field / Adam Cowen | |
| | |
+--------------------------------------+--------------------------------------+
| Financial Dynamics | Tel: [phone] |
| Ben Brewerton / Emma Thompson | |
+--------------------------------------+--------------------------------------+


Collins Stewart Europe Limited ("Collins Stewart") which is regulated in the
United Kingdom by The Financial Services Authority is acting for the Company in
relation to the matters described in this announcement and is not advising any
other person, and accordingly will not be responsible to anyone other than the
Company for providing the protections afforded to customers of Collins Stewart
or for providing advice in relation to the matters described in this
announcement.


About York Pharma (YRK.L)


York Pharma is a pharmaceutical group, established in 2003, which develops,
markets and supplies branded dermatological products to pharmaceutical
wholesalers, hospitals and general practitioners within the field of
dermatology.


Dealing Disclosure Requirements


Under the provisions of Rule 8.3 of the City Code, if any person is, or becomes,
"interested" (directly or indirectly) in 1% or more of any class of "relevant
securities" of the Company, all "dealings" in any "relevant securities" of the
Company (including by means of an option in respect of, or a derivative
referenced to, any such "relevant securities") must be publicly disclosed by no
later than 3.30pm (London time) on the Business Day following the date of the
relevant transaction. This requirement will continue until the offer lapses or
is otherwise withdrawn or the date on which the "offer period" otherwise ends.
If two or more persons act together pursuant to an agreement or understanding,
whether formal or informal, to acquire an "interest" in "relevant securities" of
the Company, they will be deemed to be a single person for the purpose of Rule
8.3 of the City Code.


Under the provisions of Rule 8.1 of the City Code, all "dealings" in "relevant
securities" of the Company by the Company, the Lender or their "associates" must
be disclosed by no later than 12.00 noon (London time) on the Business Day
following the date of the relevant transaction.


A disclosure table, giving details of the companies in whose "relevant
securities" "dealings" should be disclosed, and the number of such securities in
issue, can be found on the Panel's website at www.thetakeoverpanel.org.uk.


"Interests in securities" arise, in summary, when a person has long economic
exposure, whether conditional or absolute, to changes in the price of
securities. In particular, a person will be treated as having an "interest" by
virtue of the "ownership" or control of securities, or by virtue of any option
in respect of, or derivative referenced to, securities.


Terms in quotation marks are defined in the City Code, which can also be found
on the Panel's website. If you are in any doubt as to whether or not you are
required to disclose a "dealing" under Rule 8, you should consult the Panel.





This information is provided by RNS
The company news service from the London Stock Exchange
END

[topinfo] 01/4/2009 15:19

Only temporary blip whilst they sort out funding/takeover. I think these will relist quite quickly. They had to suspend as per Aim Listing rules as unable to get results out before 31st March 2009. I still think we will see a bid at around 8p per share. If they get funding and relist its heading north or if they get full bid....if not then ???

[wetdream] 31/3/2009 11:35

or 'twice in a lifetime' in Sadler's case.

[roorontev] 31/3/2009 08:01

R.I.P.....Another "once in a life time" AIM stock gone....;-((

[ursamajorra] 31/3/2009 07:34

RNS Number : 7656P
York Pharma plc
31 March 2009

?
31 March 2009


York Pharma Plc
(the "Company")


Suspension of trading of securities on AIM


On 20 March 2009, the Board of the Company announced that it was in discussions
with two potential offerors and that these discussions included the provision of
the necessary short term funding facilities to allow the Company to continue
trading through the period needed to complete any formal offer for the Company
under the Takeover Code.


It was also announced on 20 March 2009 that the publication of the Company's
results for the financial year ended 30 September 2008 (the "Results") would
only take place after the Company had secured its short term funding needs.
Discussions with the parties continue. However, as such short term funding is
not yet available, the Company will now not be able, as required by the AIM
Rules, to publish its Results prior to 31 March 2009. Accordingly, in
accordance with the AIM Rules, all the Ordinary Shares and Warrants have been
temporarily suspended today from trading on AIM, pending the publication of the
Company's Results.


The Board will provide a further update as and when appropriate.

[ursamajorra] 31/3/2009 07:32

NOTICE


(221)


31/03/2009 7:30am


TEMPORARY SUSPENSION OF TRADING ON AIM


YORK PHARMA PLC


Trading on AIM for the under-mentioned securities has been temporarily suspended
from 31/03/2009 7:30am pending publication of the company's annual audited
report and accounts.